

Amphastar Pharmaceuticals, Inc.  
Form 8-K  
June 22, 2015

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event Reported): June 22, 2015

**Amphastar Pharmaceuticals, Inc.**

(Exact Name of Registrant as Specified in Charter)

<b>Delaware</b> (State or Other Jurisdiction of Incorporation)	<b>001-36509</b> (Commission File Number)	<b>33-0702205</b> (I.R.S. Employer Identification Number)
<b>11570 6th Street</b> <b>Rancho Cucamonga, California</b> (Address of Principal Executive Offices)	<b>91730</b> (Zip Code)	<b>91730</b> (Zip Code)
Registrant's telephone number, including area code: <b>(909) 980-9484</b>		

**Not Applicable**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

**Item 8.01. Other Events.**

On June 22, 2015, Amphastar Pharmaceuticals, Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration ("FDA") has approved the Company's New Drug Application supplement for Amphadase® (hyaluronidase injection). The starting material for Amphadase® will be made in the Company's subsidiary, Amphastar Nanjing Pharmaceuticals Co., Ltd., which is located in Nanjing, China, and marks the first product approval that is expected to be commercialized through the use of this facility.

A copy of the press release containing the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press Release dated June 22, 2015

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 22, 2015

Amphastar Pharmaceuticals, Inc.

By: /s/ WILLIAM J. PETERS  
William J. Peters  
Chief Financial Officer and Senior Vice President

---

**EXHIBIT INDEX**

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press Release dated June 22, 2015